389
Views
5
CrossRef citations to date
0
Altmetric
Drug Discovery Case History

The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease

, , , , , , , , & show all
Pages 993-1003 | Received 13 Dec 2019, Accepted 07 May 2020, Published online: 26 May 2020
 

ABSTRACT

Introduction

Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor that is approved for the treatment of Parkinson’s disease (PD) associated with L-DOPA/L-amino acid decarboxylase inhibitor (DDI) therapy allowing for prolonged activity due to a more continuous supply of L-DOPA in the brain. Thus, OPC decreases fluctuation in L-DOPA plasma levels and favors more constant central dopaminergic receptor stimulation, thus improving PD symptomatology.

Areas covered

This review evaluates the preclinical development, pharmacology, pharmacokinetics and safety profile of OPC. Data was extracted from published preclinical and clinical studies published on PUBMED and SCOPUS (Search period: 2000–2019). Clinical and post-marketing data are also evaluated.

Expert opinion

OPC is a third generation COMT inhibitor with a novel structure. It has an efficacy and tolerability superior to its predecessors, tolcapone (TOL) and entacapone (ENT). It also provides a safe and simplified drug regimen that allows neurologists to individually adjust the existing daily administration of L-DOPA. OPC is indicated as an adjunctive therapy to L-DOPA/DDI in patients with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations.

Article highlights

  • Opicapone is a third generation COMT inhibitor.

  • Opicapone is administered once a day.

  • Opicapone has high affinity to COMT as well as a slow dissociation constant and a prolonged duration of action.

  • Opicapone is a better therapeutic agent than both ENT and TOL in patients with PD experiencing end-of-dose-fluctuations when used in combination with L-DOPA/DDI.

  • Opicapone reduces ¨off ¨ time and increases ¨on¨ time.

  • The therapeutic benefits of Opicapone 50mg are maintained without dose adjustment of L-DOPA/DDI for at least one year.

Acknowledgments

The authors thank WS Allyn MD, for reviewing the manuscript, providing corrections and his constructive criticism.

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

The authors are funded by the Spanish Ministry of Science and Innovation via grants [SAF2017-84283-R and CB06/05/0024] (CIBERNED), as well as European Regional Development Funds. The research team from the University of Barcelona and University Rovira i Virgili belongs to the Grup de Recerca en Envelliment i Neurodegeneració (Ref: 2017SGR625) from the Generalitat de Catalunya. PR Manzine is supported by grants [2015/26084-1 and 2017/13224-5] from the Sao Paulo Research Foundation (FAPESP) – Brazil.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.